- Home
- APRE vs BIAF Comparison
APRE vs BIAF Comparison
Compare APRE & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- BIAF
- Stock Information
- Founded
- APRE 2006
- BIAF 2014
- Country
- APRE United States
- BIAF United States
- Employees
- APRE N/A
- BIAF N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- APRE Health Care
- BIAF Health Care
- Exchange
- APRE Nasdaq
- BIAF Nasdaq
- Market Cap
- APRE 15.8M
- BIAF 14.5M
- IPO Year
- APRE 2019
- BIAF 2022
- Fundamental
- Price
- APRE $3.05
- BIAF $0.99
- Analyst Decision
- APRE Strong Buy
- BIAF Strong Buy
- Analyst Count
- APRE 2
- BIAF 1
- Target Price
- APRE $15.50
- BIAF $6.00
- AVG Volume (30 Days)
- APRE 22.6K
- BIAF 148.8K
- Earning Date
- APRE 11-07-2024
- BIAF 11-14-2024
- Dividend Yield
- APRE N/A
- BIAF N/A
- EPS Growth
- APRE N/A
- BIAF N/A
- EPS
- APRE N/A
- BIAF N/A
- Revenue
- APRE $1,310,839.00
- BIAF $9,367,785.00
- Revenue This Year
- APRE $134.21
- BIAF $285.51
- Revenue Next Year
- APRE N/A
- BIAF $20.05
- P/E Ratio
- APRE N/A
- BIAF N/A
- Revenue Growth
- APRE 130.31
- BIAF 2813.87
- 52 Week Low
- APRE $2.15
- BIAF $0.83
- 52 Week High
- APRE $8.85
- BIAF $3.62
- Technical
- Relative Strength Index (RSI)
- APRE 43.20
- BIAF 41.69
- Support Level
- APRE $3.02
- BIAF $0.83
- Resistance Level
- APRE $3.39
- BIAF $1.04
- Average True Range (ATR)
- APRE 0.30
- BIAF 0.13
- MACD
- APRE -0.01
- BIAF 0.02
- Stochastic Oscillator
- APRE 3.85
- BIAF 35.25
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.